The central puzzle that the POWERS Collection addresses is a phenomenon familiar to virtually everyone who has attempted sustained weight loss: the body does not accept a reduced weight passively. Decades of research have established that when a person loses a significant amount of weight, a cascade of compensatory physiological changes is triggered. Energy expenditure falls by more than would be predicted from the loss of body mass alone, a process often described as adaptive thermogenesis. At the same time, circulating hormones that signal hunger, most notably ghrelin released from the stomach, tend to rise, while satiety hormones such as leptin, which is produced by fat cells and normally signals the brain to reduce food intake, fall sharply. The net effect is a body that is simultaneously burning fewer calories and demanding more food, a combination that powerfully favors weight regain.

This coordinated defense of body weight is thought to be an evolutionary legacy. For most of human history, body fat served as an energy reserve against famine, and individuals whose physiology defended those reserves during periods of scarcity were more likely to survive and reproduce. In the modern food environment, where calorie-dense foods are constantly available and physical activity is often optional, that same survival machinery works against people who have deliberately lost weight. The weight reduced state is therefore not simply a lighter version of the original body; it is a physiologically distinct state with altered hormonal signaling, modified metabolism, and changed patterns of substrate use. Understanding exactly how these systems are rewired, and for how long the rewiring persists, is the scientific territory that the POWERS articles set out to map.

One of the most clinically important questions in this field concerns the duration of metabolic adaptation. Early studies suggested that some of the hormonal changes seen after weight loss might persist for a year or more, keeping appetite elevated long after the diet has ended. Later work has produced a more nuanced picture, with some measurements returning toward baseline over time while others remain altered, particularly in people who have maintained a large weight loss for extended periods. Studies of individuals who have successfully maintained substantial weight losses, sometimes for years, offer a valuable natural experiment: if some people can hold a reduced weight despite these pressures, identifying what differs about their physiology or behavior could point the way toward more effective maintenance strategies for everyone else.

The composition of the weight that is lost also matters enormously, and this is another theme that runs through the physiology of the weight reduced state. Energy restriction does not selectively strip away fat; it also consumes lean tissue, including skeletal muscle. Because muscle is metabolically active tissue, its loss contributes to the decline in resting energy expenditure that accompanies dieting. Resistance training and adequate protein intake during weight loss are among the strategies studied for preserving lean mass, and the degree to which they succeed influences how much of the metabolic slowdown a dieter experiences. Beyond muscle, changes in the efficiency of the mitochondria, the cellular power plants that convert fuel into usable energy, and in the activity of brown and beige fat, which dissipate energy as heat, may all contribute to the reduced energy expenditure of the weight reduced state.

Appetite regulation adds a second, equally complex layer. The brain integrates signals from hormones circulating in the blood, from the vagus nerve carrying information about the state of the gut, and from higher cognitive and emotional centers, and it uses this information to generate the sensations of hunger and fullness. After weight loss, the balance of these signals shifts toward hunger. Functional imaging studies have shown that people in a weight reduced state display altered brain responses to images of food, with heightened activity in regions associated with reward and reduced activity in areas associated with restraint. Whether these neural changes are a cause of weight regain or a consequence of the altered hormonal milieu remains an open question, and disentangling cause from effect is one of the methodological challenges that careful longitudinal studies are designed to address.

Against this background, the publication of a dedicated collection is significant for the field. The International Journal of Obesity is one of the leading venues for obesity research, and by gathering six articles on the weight reduced state in one place, the POWERS Collection signals that weight loss maintenance has moved from the margins of obesity science to its center. The two articles published in January 2026, available at doi.org/10.1038/s41366-025-01851-0 and doi.org/10.1038/s41366-025-01911-5, together with the four articles in the September special chapter, available at doi.org/10.1038/s41366-025-01935-x, doi.org/10.1038/s41366-025-01932-0, doi.org/10.1038/s41366-025-01944-w and doi.org/10.1038/s41366-025-01991-3, collectively form a snapshot of where the science stands. Collections of this kind serve an important function beyond convenience: they allow researchers working on individual pieces of the puzzle to see their findings in the context of the whole, and they give newcomers to the field an efficient entry point.

The practical stakes of this research are hard to overstate. Obesity now affects hundreds of millions of people worldwide and is associated with type 2 diabetes, cardiovascular disease, several cancers, and reduced life expectancy. The arrival of highly effective new medications for weight loss has transformed the treatment landscape, but it has also sharpened the maintenance question: what happens to the physiology of patients who lose large amounts of weight pharmacologically, and how should treatment be sustained? The classical studies of the weight reduced state were conducted largely in the era of diet and exercise interventions, and the field now faces the task of determining whether the same adaptive responses emerge after medication-induced or surgically induced weight loss, and whether they can be blunted. Research on the fundamental physiology of the reduced weight state provides the framework within which those newer questions can be answered.

There is also a message in this science for the millions of people who have struggled with weight regain and blamed themselves for a lack of willpower. The evidence assembled across the obesity literature shows that the weight reduced body actively resists further loss and actively promotes regain through mechanisms that operate below conscious awareness. Hunger hormones rise, satiety signals fade, energy expenditure drops, and the brain’s response to food cues intensifies. Recognizing that these responses are biological rather than moral failures reframes the maintenance challenge as a medical problem that deserves medical and behavioral solutions, from structured support programs to pharmacological maintenance therapy. It also underscores why even modest long-term weight losses, which are more achievable than dramatic ones, deliver meaningful health benefits.

The POWERS Collection, published in volume 50 of the International Journal of Obesity and introduced in an editorial by David Stensel, represents a deliberate effort to consolidate knowledge at a moment when public and scientific interest in weight regulation has never been higher. As the six articles are read together, they offer researchers a common reference point for the adaptations that define the weight reduced state and for the open questions that remain, including how long these adaptations persist, why they vary between individuals, and how they can be overcome. For a field in which the gap between losing weight and keeping it off has defined decades of frustration, that consolidation is a step toward interventions built on physiology rather than on hope alone.

Subject of Research: Physiological adaptations underlying weight loss and weight-loss maintenance

Article Title: Physiology of the Weight Reduced State (POWERS) Collection

Article References: Stensel, D. (2026). Physiology of the Weight Reduced State (POWERS) Collection. International Journal of Obesity, 50(9), 1857-1857. https://doi.org/10.1038/s41366-026-02219-8

Image Credits: AI Generated

DOI: 10.1038/s41366-026-02219-8

Keywords: obesity, weight loss maintenance, adaptive thermogenesis, leptin, ghrelin, energy expenditure, appetite regulation, metabolism, POWERS Collection, International Journal of Obesity, weight reduced state, hormonal adaptation

The study, led by Chia Siang Kow and colleagues, took a fresh statistical look at the six clinical studies and ten intervention arms that tracked semaglutide or tirzepatide after treatment discontinuation, drawing on data covering 1776 participants. Rather than relying on simple pooled averages, the researchers reconstructed the arm-level data and applied a Bayesian hierarchical longitudinal model, a statistical framework that jointly models repeated measurements over time while explicitly accounting for variability between study arms. This approach allowed the team to go beyond asking how many kilograms are regained each month and instead translate the trajectory into clinically meaningful milestones, complete with full probability distributions that quantify uncertainty.

The headline finding is that people who stop taking these medications regain an estimated 1.04 kilograms per month on average, with a 95 percent credible interval of 0.80 to 1.29 kilograms per month. The modelled average participant had lost 15.35 kilograms by the time treatment ended. Under the linear model assumed by the researchers, half of that hard-won loss was projected to return within about 7.5 months, and participants were projected to be back at their baseline weight by roughly 15 months after stopping. In practical terms, the clock on the treatment’s benefits starts ticking almost the moment the final injection wears off.

The month-by-month trajectory is particularly striking. Within the follow-up window actually observed in the trials, which extended to 52 weeks, the modelled average weight change was still below baseline at six months, at minus 9.12 kilograms, but by then approximately 41 percent of the initial weight loss had already been regained. At nine months the average was minus 6.01 kilograms, corresponding to 62 percent regained, and by twelve months the average stood at minus 2.90 kilograms, meaning roughly 83 percent of the lost weight had returned. The posterior probability that the average trajectory had regained at least half of the initial weight loss climbed from just 12.5 percent at six months to 86.7 percent at nine months and a near-certain 99.5 percent at one year.

It is important to understand the mathematical machinery behind these numbers. The researchers assumed a constant linear regain slope rather than a curving trajectory, a choice justified because follow-up data were sparse and a prior systematic review had found that adding a nonlinear term did not improve model fit. Each study arm was treated as a repeated-measures trajectory with its own random effects for both the weight loss present at discontinuation and the subsequent regain rate. The Bayesian estimation relied on full Markov chain Monte Carlo sampling, with convergence confirmed by R-hat statistics hovering at approximately 1.00 and large effective sample sizes for the key slope parameters. Estimates extending beyond the maximum observed follow-up of 52 weeks, including the projected return to baseline at 15 months, are explicitly flagged as extrapolations of the average trajectory rather than directly observed outcomes.

One of the most provocative aspects of the analysis is its comparison of the two drugs. Tirzepatide arms showed a numerically faster unadjusted regain rate of 1.10 kilograms per month compared with 0.89 kilograms per month for semaglutide, and projected return to baseline was correspondingly sooner, at roughly 14.5 months versus 17.3 months. But when the researchers adjusted for the magnitude of initial weight loss and post-discontinuation support in a Bayesian meta-regression, the drug difference essentially vanished. The adjusted effect of tirzepatide versus semaglutide was a negligible minus 0.04 kilograms per month, with a posterior probability of only 40.2 percent that tirzepatide regains faster. In other words, the apparent difference in rebound between the two drugs likely reflects differences in how much weight was lost in the first place, not any inherent difference in the physiology of regain.

That observation points to one of the study’s most interesting exploratory findings: greater initial weight loss was itself the strongest directional predictor of faster absolute regain. Each additional 5 kilograms of weight lost during treatment was associated with a 0.20 kilograms per month faster regain slope, a result carrying a 92.1 percent posterior probability, though the credible interval included zero. The authors caution that this association may partly reflect mathematical coupling, since a larger initial loss simply creates more opportunity for absolute regain. Meanwhile, behavioural or lifestyle support after discontinuation showed a directional association with slower regain, an estimated effect of minus 0.19 kilograms per month with an 87.2 percent probability of benefit, but the imprecise estimate means the finding remains inconclusive. With only ten intervention arms available, all meta-regression results are explicitly exploratory and hypothesis-generating rather than definitive.

Sensitivity analyses reinforced the robustness of the core conclusion. A contrast analysis using the randomised differences between intervention and control arms showed a similar direction of effect, though with less precision. A post hoc analysis excluded the three SURPASS-1 arms, which came from a trial of adults with Type 2 diabetes receiving tirzepatide as glucose-lowering monotherapy rather than for weight management. Excluding those arms left the monthly regain slope essentially unchanged at 0.95 kilograms per month, though the projected time to 50 percent regain lengthened to 9.42 months because the average initial weight loss among the remaining arms was greater. The qualitative message of rapid regain survived every stress test the researchers applied.

The clinical implications are considerable. Because discontinuation is common in routine practice, driven by cost, tolerability problems, access restrictions, treatment fatigue and genuine uncertainty about how long therapy should last, the findings suggest that clinicians should plan proactive monitoring within the first several months after stopping treatment, when early regain can be identified and maintenance strategies reassessed. The authors are careful to note that their data do not determine whether dose tapering, lower-dose maintenance, drug switching, intermittent treatment or any specific behavioural programme can prevent regain; those questions require dedicated trials. They also stress that the analysis captured body-weight trajectories only, so any statements about cardiometabolic benefits, cost-effectiveness or the consequences of fixed-duration treatment policies remain hypotheses informed by the weight pattern rather than direct findings.

What the study ultimately delivers is a statistically rigorous quantification of something patients and clinicians have long suspected: incretin-based anti-obesity medications suppress appetite and enable weight loss while they are active, and withdrawing that physiological support removes the very mechanism holding the weight down. Between-study heterogeneity was real but moderate, with a between-arm standard deviation of 6.78 kilograms for initial weight loss and 0.26 kilograms per month for the regain slope, suggesting that while individual experiences vary, the average trajectory is consistently steep. As these drugs reshape obesity medicine and public expectations, the analysis argues that their long-term value must be judged not only by the dramatic losses achieved during treatment but by an honest accounting of what follows when the treatment ends, and by research that extends follow-up beyond one year, reports regain in both absolute and percentage terms, and directly tests the maintenance strategies that patients will increasingly demand.

Subject of Research: Weight regain after discontinuation of the incretin-based anti-obesity medications semaglutide and tirzepatide

Article Title: Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate‐Data Bayesian Longitudinal Meta‐Analysis

Article References: Kow, C. S., Thiruchelvam, K., Ramachandram, D. S., & Zaihan, A. F. (2026). Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate‐Data Bayesian Longitudinal Meta‐Analysis. Endocrinology, Diabetes & Metabolism, 9(5), Article e70325. https://doi.org/10.1002/edm2.70325

Image Credits: AI Generated

DOI: 10.1002/edm2.70325

Keywords: semaglutide, tirzepatide, weight regain, obesity, incretin therapies, GLP-1 receptor agonists, Bayesian meta-analysis, treatment discontinuation, weight loss maintenance, anti-obesity pharmacotherapy, Weight, Regain